We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

A groundbreaking study on a new rapid test that identifies COVID-19 patients who will deteriorate with greater accuracy than existing tests was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

A team of researchers from MeMed (Haifa, Israel) has developed the test that predicts COVID-19 outcomes with high accuracy. In 15 minutes, the test measures blood levels of TRAIL and IP-10, two proteins that the immune system produces in response to viral infections, and CRP, a general marker of infection severity. The test then uses these values to calculate a COVID-19 Severity score on a scale of 0-100, with 100 indicating the highest likelihood of severe outcome.

To develop this test, the researchers first used a rapid point-of-care instrument that MeMed previously built to measure TRAIL, IP-10, and CRP in a group of 518 COVID-19 patients, 113 of whom had a severe outcome. The researchers analyzed the data from this group with a machine learning algorithm in order to create the model that serves as the basis for the COVID-19 Severity score. Through statistical analysis, the researchers then determined that the COVID-19 Severity score has an area under the curve (AUC) of 0.86. This means that it outperforms other COVID-19 severity stratification tests in terms of accuracy, including the commonly used biomarker IL-6, which only has an AUC of 0.77.

“There are three elements that are novel about this test,” said Eran Eden, PhD, Co-founder & CEO of MeMed. “First, we’re using the body’s immune response to tell us what’s going on with the patient. Second, instead of using just one biomarker, we’re combining three complementary markers to get a more holistic picture. And third, we’re using a novel platform that is able to measure these specific proteins from blood within 15 minutes, making this test clinically applicable to the workflow in today’s emergency departments.”

Related Links:
MeMed

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
TRAb Immunoassay
Chorus TRAb

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.